StockData
First Tracks Biotherapeutics, Inc. logo

First Tracks Biotherapeutics, Inc. (TRAX) stock

TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$44.50+0.93 (+2.13%)

Close on Nov 18, 2026Market cap $1.59BP/E –Yield –

First Tracks Biotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$17.05M–
Q2 FY2026Jun 30, 2026-$31.94M–
Q1 FY2026Mar 31, 2026-$32.58M–
Q3 FY2025Sep 30, 2025-$30.70M–
Q2 FY2025Jun 30, 2025-$38.68M–
Q1 FY2025Mar 31, 2025-$45.04M–

More First Tracks Biotherapeutics figures

See a number that looks wrong?